文献速递主动脉疾病

消退素D1通过抑制NETosis减少小鼠模型腹主动脉瘤形成

Resolvin D1 decreases abdominal aortic aneurysm formation by inhibiting NETosis in a mouse model.
PubMed 文献 · J Vasc Surg · 2018-01-01

研究在两种小鼠腹主动脉瘤模型中验证消退素D1(RvD1)的作用:局部弹性蛋白酶模型(野生型C57BL/6雄性小鼠,n=47)和血管紧张素II诱导模型(载脂蛋白E缺陷小鼠,n=20)。RvD1治疗组第14天腹主动脉瘤直径较弹性蛋白酶组减少42%(P < .001),并降低NETosis标志物及促炎细胞因子、升高保护性细胞因子IL-10。作者认为RvD1介导的NETosis抑制可能成为未来延缓腹主动脉瘤生长的药物治疗。

要点

  • RvD1治疗组第14天腹主动脉瘤直径较弹性蛋白酶组减少42%(P < .001)。
  • RvD1治疗组第3天瓜氨酸化组蛋白H3(P = .04)和中性粒细胞弹性蛋白酶(P = .002)较弹性蛋白酶组降低。
  • 血管紧张素II模型中RvD1治疗组第28天腹主动脉瘤直径较对照缩小(P < .046)。

核心结论

  • RvD1介导的NETosis抑制可能代表未来延缓腹主动脉瘤生长的药物治疗。

研究设计与样本

  • 野生型8至12周龄C57BL/6雄性小鼠(n = 47)和载脂蛋白E缺陷(ApoE-/-)小鼠(n = 20)用于两种模型以证明RvD1对腹主动脉瘤生长的作用。
  • 局部弹性蛋白酶模型分三组:灭活弹性蛋白酶对照组(假手术,每日静脉注射磷酸盐缓冲液直至取材)、弹性蛋白酶组(活性弹性蛋白酶诱导腹主动脉瘤,每日注射磷酸盐缓冲液直至取材)、RvD1治疗组(诱导腹主动脉瘤后每日注射RvD1直至取材)。
  • 血管紧张素II诱导模型:ApoE-/-小鼠高脂饮食并植入渗透泵输注血管紧张素II(1000 ng/kg/min),分两组:血管紧张素II对照组(每日注射磷酸盐缓冲液直至取材)和RvD1治疗组(每日注射RvD1直至取材)。
  • 术后第3天、第14天或第28天测量主动脉直径后收集主动脉和血样,行Western blot、组织学、细胞因子阵列、酶联免疫吸附测定和明胶酶谱分析。

主要发现

  • 第14天RvD1治疗组腹主动脉瘤直径较弹性蛋白酶组减少42%(P < .001)。
  • 术后第3天RvD1治疗组NETosis标志物瓜氨酸化组蛋白H3(P = .04)和中性粒细胞弹性蛋白酶(P = .002)水平较弹性蛋白酶组降低。
  • RvD1治疗组白介素1β下调(P = .02),保护性细胞因子白介素10上调(P = .01)。
  • RvD1治疗组活性基质金属蛋白酶2降低(P = .03)。
  • 血管紧张素II模型中RvD1治疗组第28天腹主动脉瘤直径较血管紧张素II对照组缩小(P < .046),第3天瓜氨酸化组蛋白H3水平降低(P = .002),第28天干扰素γ、白介素1β、C-X-C基序趋化因子配体10、单核细胞趋化蛋白1和调节激活正常T细胞表达和分泌因子均降低(P < .05)。

临床怎么用

  • 作者认为RvD1介导的NETosis抑制可能成为未来延缓腹主动脉瘤生长的药物治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Resolvins have been shown to attenuate inflammation, whereas NETosis, the process of neutrophils releasing neutrophil extracellular traps (NETs), produces increased inflammation. It is hypothesized that treatment of animals with resolvin D1 (RvD1) would reduce abdominal aortic aneurysm (AAA) formation by inhibiting NETosis. METHODS: Wild-type 8- to 12-week-old C57BL/6 male mice (n = 47) and apolipoprotein E-deficient (ApoE-/-) mice (n = 20) were used in two models to demonstrate the effects of RvD1 on AAA growth. In the topical elastase AAA model, wild-type mice were divided into three groups: a deactivated elastase control group, in which sham surgery was performed using deactivated elastase and mice were intravenously injected with phosphate-buffered saline (PBS) once a day until harvest; an elastase group, in which active elastase was used to induce AAA and mice were injected with PBS daily until harvest; and an RvD1-treated group, in which AAA was induced and mice were injected with RvD1 daily until harvest. In the angiotensin II (Ang II)-induced AAA model, ApoE-/- mice were fed a high-fat diet and implanted with osmotic infusion pumps containing Ang II (1000 ng/kg/min). The Ang II model was divided into two groups: an Ang II control group, in which Ang II was delivered and mice were injected with PBS daily until harvest; and an RvD1-treated group, in which Ang II was delivered and mice were injected with RvD1 daily until harvest. On postoperative day 3, day 14, or day 28, aortic and blood samples were collected for Western blot, histology, cytokine array, enzyme-linked immunosorbent assay, and gelatin zymography after aortic diameter measurement. RESULTS: The day 14 RvD1-treated group demonstrated 42% reduced AAA diameter compared with the elastase group (P < .001). On postoperative day 3, the RvD1-treated group showed decreased levels of NETosis markers citrullinated histone H3 (P = .04) and neutrophil elastase (P = .002) compared with the elastase group. Among important cytokines involved in AAA formation, interleukin (IL) 1β was downregulated (P = .02) whereas IL-10, a protective cytokine, was upregulated (P = .01) in the RvD1-treated group. Active matrix metalloproteinase 2 also decreased in the RvD1-treated group (P = .03). The RvD1-treated group in the Ang II AAA model, a second model, demonstrated reduced AAA diameter compared with the Ang II control group on day 28 (P < .046). The RvD1-treated group showed decreased levels of citrullinated histone H3 on day 3 (P = .002). Cytokines interferon γ, IL-1β, C-X-C motif chemokine ligand 10, monocyte chemotactic protein 1, and regulated on activation, normal T cell expressed and secreted (RANTES) were all decreased on day 28 (P < .05). CONCLUSIONS: RvD1-mediated inhibition of NETosis may represent a future medical treatment for the attenuation of AAA growth.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Spinosa M, Su G, Salmon MD, et al. Resolvin D1 decreases abdominal aortic aneurysm formation by inhibiting NETosis in a mouse model. J Vasc Surg. 2018. PMID: 30470363. doi:10.1016/j.jvs.2018.05.253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。